Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,383 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05475613RecruitingPhase 2
Immunotherapy to shrink advanced liver cancer before transplant
This trial tests an immunotherapy “downstaging” plan to shrink hepatocellular carcinoma (a type of liver cancer) so it may become treatable with a liver transplant. You may be eligible if your cancer is beyond transplant limits but is still only in the liver, and you meet specific liver function and health requirements.
Guangzhou, GuangdongAges 18–75 - NCT05482516RecruitingPhase 3
Testing blood test–guided treatment for GI cancers in remission
This Phase 3 study tests whether giving treatment based on a positive blood test for “minimal cancer signals” (ctDNA) can help people with certain GI cancers stay cancer-free longer. It focuses on people who have finished curative-intent therapy and currently have no visible disease on scans, but their blood test is still positive.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05483374Recruiting
Head and neck cancer registry for adult patients
This study builds a European database (registry) of adults with certain head and neck cancers to better understand how these cancers are diagnosed and treated over time. It may help future care by collecting real-world information, rather than testing a new medicine.
Brno, BrnoAges 18 years+ - NCT05487092Recruiting
Letrozole to help prevent endometrioma coming back after surgery
This study tests whether taking letrozole after laparoscopic ovarian cyst surgery can lower the chance that an endometrioma (a type of ovarian endometriosis cyst) comes back. It may help some people reduce recurrence after the cyst is removed.
Hong KongAges 18–45 - NCT05492136Recruiting
Radiofrequency during liver surgery to reduce cancer coming back
This study looks at whether using radiofrequency (a heat-based treatment used during surgery) during liver surgery can lower the chances that cancer returns locally. It includes people with colorectal cancer that has spread to the liver and people with liver cancer (HCC).
BarcelonaAges 18 years+ - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75 - NCT05518305Recruiting
Predicting recurrent stroke risk in people with artery narrowing
This study looks at blood markers and brain/artery scan results to predict who with intracranial artery narrowing is more likely to have another stroke. It may help doctors spot higher-risk people earlier and better target prevention.
Los Angeles, CaliforniaAges 30 years+ - NCT05520034Recruiting
Nurse teaching plan to help prevent another stroke
This study tests whether nurse-led education and follow-up can lower the chance of having another stroke. It targets people who recently returned home after a first stroke and their main caregiver.
DhakaAges 18 years+ - NCT05522881Recruiting
Study of genetic changes in oropharyngeal cancer tumors
This study collects information and tumor tissue to look for genetic changes in oropharyngeal cancer, especially in patients whose cancer has come back. The goal is to better understand the disease and may help future treatment planning.
Kaohsiung CityAges 20 years+ - NCT05532397Recruiting
Tested lab-chosen drug combo for recurrent brain tumor
This study uses a patient’s tumor tissue to test drug combinations in the lab, aiming to help choose a better second-line treatment for recurrent high-grade astrocytic glioma. If your tumor tissue can be tested, the results may guide a more personalized medication plan.
SingaporeAges 21–99 - NCT05534906Recruiting
Detecting very early liver cancer and tracking its natural course
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
Oxford, OxfordshireAges 18–100 - NCT05542407RecruitingPhase 1
ONC201 plus atezolizumab for endometrial cancer and obesity
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT05556473RecruitingPhase 1
Tryptophan PET/CT scan study for different tumors
This early-phase study tests a special PET/CT scan using labeled tryptophan to help doctors see how different tumors behave. The goal is to learn whether this scan can better identify and measure cancers in the brain or elsewhere.
Detroit, MichiganAges 18 years+ - NCT05557201Recruiting
Study causes of repeated early miscarriages
This study looks at people who have had repeated early pregnancy losses to find patterns that might explain why miscarriages keep happening. It mainly involves collecting and analyzing your medical information to better understand risk factors.
ParisAges 18–50 - NCT05557474Recruiting
Test of a lung cancer prognosis kit after early tumor removal
This study tests a lab “prognosis kit” to better predict how early-stage lung cancer may progress after the tumor has been fully removed. You may be asked to provide tumor samples and possibly blood/body fluid samples so researchers can validate the kit.
Taichung, TaiwanAges 20 years+ - NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT05563922RecruitingPhase 2
Testing a plan to preserve the anus after rectal chemo-radiation
This Phase 2 study tests a “total neoadjuvant” (chemo plus radiation before the main treatment) plan to see if some people with low rectal cancer can keep their anus. It may help you avoid permanent colostomy if your cancer responds well and you meet the study rules.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05568680RecruitingPhase 1
Early trial of SynKIR-110 for certain ovarian and lung-lining cancers
This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.
Tampa, FloridaAges 18 years+ - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Miami, FloridaAges 18 years+ - NCT05576831Recruiting
Testing HPV and p53 to guide vulvar cancer surgery
This study looks at two tumor test results—HPV and p53—to help doctors decide how much tissue to remove during surgery for vulvar squamous cell carcinoma. It’s meant to reduce the risk of the cancer coming back while avoiding unnecessary removal when margins are only close.
Vancouver, British ColumbiaAges 18 years+ - NCT05576974RecruitingPhase 2
Test a dye used during surgery to find head and neck cancer
This trial tests whether a single dose of an imaging dye (given during surgery) can help doctors find the unknown origin of head and neck cancer and check safety. It may help guide surgery and biopsies when the primary cancer location hasn’t been identified.
Dallas, TexasAges 18–99 - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Phoenix, ArizonaAges 18 years+ - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,383 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.